AI-based histologic measurement of NASH (AIM-NASH): A drug development tool for assessing clinical trial end points

July 02, 2021

Study Background

Limitations of manual pathology may confound results of NASH clinical trials. Our aim was to develop an AI-based drug development tool (AIM-NASH) that reproducibly calculates NASH Clinical Research Network (CRN) scores. Prakash et al.

View Abstract

Get In Touch

PathAI Media

Company Contact

Liz Storti

Chief People Officer

elizabeth.storti@pathai.com

Media Contact

Daniel Donato

LifeSci Communications

ddonato@lifescicomms.com

516-474-0554